US halts plasma study to treat mild COVID-19, citing ‘unlikely benefit’
The National Institutes of Health announced Tuesday it stopped a clinical trial testing convalescent plasma in mild to moderate COVID-19 patients after an independent board found no difference in hospitalizations, deaths or in preventing progression to severe illness. An independent data and safety monitoring board convened on Feb. 25 to assess trial data, and concluded that while the plasma “caused no harm,...